Loading patent…
AssigneeBostal Drug Delivery Co., Ltd.
InventorsWei Li, Wenxi Yan, Rong Liu, Weiqin Tong, Xiang Li
Estimating the term…
Disclosed in the present invention is a pellet of dabigatran etexilate or a pharmaceutically acceptable salt thereof, which pellet contains a pellet core, a drug layer containing dabigatran etexilate or the pharmaceutically acceptable salt thereof, and a protective layer, wherein the drug layer containing dabigatran etexilate or the pharmaceutically acceptable salt thereof is located between the pellet core and the protective layer; the protective layer contains a water-soluble polymer and a non-water-soluble cellulose derivative having a bonded hydrophobic group; and the weight ratio of the water-soluble polymer to the non-water-soluble cellulose derivative having a bonded hydrophobic group is from 0.67:1 to 1.3:1. Compared with the prior art, the present invention reduces the risk of pellet adhesion in the capsule, so as to achieve the effects of reducing the individual variation in drug administration, stabilizing the release of organic acids and drugs, improving the bioavailability, and decreasing side effects.
A pellet of dabigatran etexilate or a pharmaceutically acceptable salt thereof, comprising a pellet core, a drug layer containing dabigatran etexilate or pharmaceutically acceptable salt thereof, and a protective layer, wherein the drug layer containing dabigatran etexilate or pharmaceutically acceptable salt thereof is located between the pellet core and the protective layer, and the protective layer comprises a water-soluble polymer and a water-insoluble cellulose derivative with bonded hydrophobic groups;
Dependencies are inferred from the claim text.